2024 Q2 Form 10-Q Financial Statement

#000121390024045020 Filed on May 20, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.390K
YoY Change -37.39%
Cash & Equivalents $1.392K
Short-Term Investments
Other Short-Term Assets $47.22K
YoY Change -5.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $48.61K
YoY Change -7.06%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.00
YoY Change -300.0%
TOTAL ASSETS
Total Short-Term Assets $48.61K
Total Long-Term Assets $4.00
Total Assets $48.61K
YoY Change -7.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.925M
YoY Change 13.06%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $96.24K
YoY Change 197.13%
Long-Term Debt Due $207.7K
YoY Change 10.48%
Total Short-Term Liabilities $2.230M
YoY Change 16.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.230M
Total Long-Term Liabilities $0.00
Total Liabilities $2.230M
YoY Change 16.01%
SHAREHOLDERS EQUITY
Retained Earnings -$28.91M
YoY Change 1.43%
Common Stock $771.8K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.182M
YoY Change
Total Liabilities & Shareholders Equity $48.61K
YoY Change -7.04%

Cashflow Statement

Concept 2024 Q2 2024 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-191083
dei Entity Registrant Name
EntityRegistrantName
ACTAVIA LIFE SCIENCES, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
39-2080103
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Penn Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
19th Floor, # 1954
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
396-4087
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
771811360 shares
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1392 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74986 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
47222 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20671 usd
CY2024Q1 us-gaap Assets
Assets
48614 usd
CY2023Q3 us-gaap Assets
Assets
95657 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1503658 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1458216 usd
CY2024Q1 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
53950 usd
CY2023Q3 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
8509 usd
CY2024Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
42294 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4730 usd
CY2024Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1862 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2036 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2230363 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2051566 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
771811360 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
771811360 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
771811360 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
771811360 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
771811 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
771811 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25953197 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25935882 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28906757 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28663602 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2181749 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1955909 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48614 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95657 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
60161 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
93955 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
166374 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
198811 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11226 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13704 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29743 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31660 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3858793 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3858793 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
71387 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
3966452 usd
us-gaap Operating Expenses
OperatingExpenses
196117 usd
us-gaap Operating Expenses
OperatingExpenses
4089264 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-71387 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3966452 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-196117 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4089264 usd
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
15837 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
164147 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
30697 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
180333 usd
CY2024Q1 us-gaap Interest Expense Other
InterestExpenseOther
8743 usd
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
6489 usd
us-gaap Interest Expense Other
InterestExpenseOther
17200 usd
us-gaap Interest Expense Other
InterestExpenseOther
18191 usd
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
449 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7888 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
859 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
8744 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24131 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-162748 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47038 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-189780 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-95518 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4129200 usd
us-gaap Net Income Loss
NetIncomeLoss
-243155 usd
us-gaap Net Income Loss
NetIncomeLoss
-4279044 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
771811360 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
588518916 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
771811360 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
384249138 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2103546 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17315 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-95518 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2181749 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1809641 usd
CY2023Q1 rasp Issuance Of Stock For The Conversion Of Promissory Notes
IssuanceOfStockForTheConversionOfPromissoryNotes
209773 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3858793 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4129200 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1870275 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1955909 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17315 usd
us-gaap Net Income Loss
NetIncomeLoss
-243155 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2181749 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1688597 usd
rasp Issuance Of Stock For The Conversion Of Promissory Notes
IssuanceOfStockForTheConversionOfPromissoryNotes
209773 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3858793 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28800 usd
us-gaap Net Income Loss
NetIncomeLoss
-4279044 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1870275 usd
us-gaap Net Income Loss
NetIncomeLoss
-243155 usd
us-gaap Net Income Loss
NetIncomeLoss
-4279044 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
16849 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
18191 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
30697 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
180333 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
859 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
8744 usd
rasp Common Stock Issued For Services
CommonStockIssuedForServices
3858793 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
45442 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
113932 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
40542 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
41596 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-27399 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-49786 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83085 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25157 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
18000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
30000 usd
rasp Payments On Note Payable
PaymentsOnNotePayable
8509 usd
rasp Payments On Note Payable
PaymentsOnNotePayable
41985 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9491 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-11985 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-73594 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-37142 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74986 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39363 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1392 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2221 usd
rasp Derivative Liabilities In Connection With Issuance Of Convertible Notes
DerivativeLiabilitiesInConnectionWithIssuanceOfConvertibleNotes
685 usd
rasp Derivative Liabilities In Connection With Issuance Of Convertible Notes
DerivativeLiabilitiesInConnectionWithIssuanceOfConvertibleNotes
1200 usd
rasp Beneficial Conversions Feature Related To Issuance Of Convertible Notes
BeneficialConversionsFeatureRelatedToIssuanceOfConvertibleNotes
17315 usd
rasp Beneficial Conversions Feature Related To Issuance Of Convertible Notes
BeneficialConversionsFeatureRelatedToIssuanceOfConvertibleNotes
28800 usd
rasp Issuance Of Common Stock For Conversions Of Promissory Notes
IssuanceOfCommonStockForConversionsOfPromissoryNotes
209773 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
108099001 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2865176 shares
CY2023Q1 us-gaap Deferred Discounts Finance Charges And Interest Included In Receivables
DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables
1187 usd
CY2023Q1 us-gaap Payments For Fees
PaymentsForFees
4626 usd
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
236 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. GENERAL INFORMATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actavia Life Sciences, Inc. (f/k/a Rasna Therapeutics, Inc. the “Company”) is a biotechnology company incorporated in the State of Delaware on March 28, 2016. The Company is engaged in modulating the molecular target LSD1, which is implicated in the disease progression of leukemia and lymphoma. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited condensed consolidated financial statements are presented in United States dollars (“USD”) which is also the functional currency of the primary economic environment in which the Company operates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management continues to evaluate the impact of inflation and the economic environment on the Company, and has concluded that while it is reasonably possible that inflation could have a negative effect on the Company’s financial position, results of its operations and/or ability to secure additional cash resources, there is no current impact as cash resources are currently secured by existing shareholders. The financial statements do not include any adjustments that might result from this uncertainty.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the fair values of share based awards, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the Company’s consolidated financial position and results of operations.</p>
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28906757 usd
us-gaap Net Income Loss
NetIncomeLoss
-243155 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83085 usd
CY2024Q1 us-gaap Derivative Cash Received On Hedge
DerivativeCashReceivedOnHedge
18000 usd
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.001
CY2024Q1 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
1000000 usd
CY2024Q1 us-gaap Investment Interest Rate
InvestmentInterestRate
0.02 pure
CY2024Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
685 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
685 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7888 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
8744 usd
CY2023Q4 rasp Beneficial Conversions Feature Related To Issuance Of Convertible Notes
BeneficialConversionsFeatureRelatedToIssuanceOfConvertibleNotes
17315 usd
CY2023Q1 rasp Beneficial Conversions Feature Related To Issuance Of Convertible Notes
BeneficialConversionsFeatureRelatedToIssuanceOfConvertibleNotes
28800 usd
CY2024Q1 us-gaap Funds Held Under Reinsurance Agreements Asset
FundsHeldUnderReinsuranceAgreementsAsset
53950 usd
CY2024Q1 us-gaap Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
13500 usd
CY2024Q1 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.0799 pure
CY2024Q1 us-gaap Deferred Discounts Finance Charges And Interest Included In Receivables
DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables
1359 usd
CY2024Q1 us-gaap Payments For Fees
PaymentsForFees
4645 usd
CY2024Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
270 usd
CY2023Q1 us-gaap Funds Held Under Reinsurance Agreements Asset
FundsHeldUnderReinsuranceAgreementsAsset
53950 usd
CY2023Q1 us-gaap Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
13500 usd
CY2023Q1 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.0699 pure
CY2024Q1 us-gaap Compensating Balance Amount
CompensatingBalanceAmount
175000 usd
CY2023Q3 us-gaap Compensating Balance Amount
CompensatingBalanceAmount
175000 usd
CY2024Q1 us-gaap Cash And Due From Banks
CashAndDueFromBanks
87360 usd
CY2020Q1 us-gaap Loans Payable
LoansPayable
65000 usd
CY2020Q2 us-gaap Loans Payable
LoansPayable
7000 usd
CY2020Q2 us-gaap Other Loans Payable
OtherLoansPayable
72000 usd
CY2024Q1 us-gaap Loans Payable
LoansPayable
95040 usd
CY2023Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
93600 usd
CY2022Q3 us-gaap Loans Payable
LoansPayable
85000 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
384249138 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
588518916 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
771811360 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
771811360 shares
rasp Common Stock Issued For Services
CommonStockIssuedForServices
usd
rasp Issuance Of Common Stock For Conversions Of Promissory Notes
IssuanceOfCommonStockForConversionsOfPromissoryNotes
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001582249

Files In Submission

Name View Source Status
0001213900-24-045020-index-headers.html Edgar Link pending
0001213900-24-045020-index.html Edgar Link pending
0001213900-24-045020.txt Edgar Link pending
0001213900-24-045020-xbrl.zip Edgar Link pending
ea0206516-10q_actavia.htm Edgar Link pending
ea020651601ex31-1_actavia.htm Edgar Link pending
ea020651601ex32-1_actavia.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rasp-20240331.xsd Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ea0206516-10q_actavia_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
rasp-20240331_cal.xml Edgar Link unprocessable
rasp-20240331_def.xml Edgar Link unprocessable
rasp-20240331_pre.xml Edgar Link unprocessable
rasp-20240331_lab.xml Edgar Link unprocessable